Top

Published in:

01-03-2011 | Original Research Article

Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome

The MARCADOR Study

Authors: Dr Francisco J. Martinez-Martin, Alicia Macias-Batista, Cristina Comi-Diaz, Herminia Rodriguez-Rosas, Paula Soriano-Perera, Pablo Pedrianes-Martin

Published in: Clinical Drug Investigation | Issue 3/2011

Abstract

Background and Objective: Metabolic syndrome is common in patients with hypertension and increases the risk of developing diabetes mellitus. The objective of this study (the MARCADOR study) was to compare the effects of manidipine 20 mg with the extemporary combination of manidipine 10mg/lisinopril 10 mg, amlodipine 10 mg and telmisartan 80 mg on insulin sensitivity, as well as metabolic, inflammatory and prothrombotic markers, in hypertensive non-diabetic patients with metabolic syndrome.

Methods: This study had a prospective, randomized, open-label, blinded endpoint (PROBE) design. A total of 120 patients aged 35–75 years with stage I—II essential hypertension (systolic blood pressure [BP] 140–179 mmHg, diastolic BP 90–109 mmHg) and metabolic syndrome were recruited from general practitioner clinics in Northern Gran Canaria Island, Spain and randomized to receive amlodipine 10 mg (n = 30), telmisartan 80 mg (n = 30), manidipine 20 mg (n = 30) or (low-dose) manidipine 10 mg/lisinopril 10 mg (n=30), all administered once daily. At baseline and after 14 weeks of treatment, BP, insulin sensitivity, lipid profile, and albumin and metanephrin excretion as well as several other metabolic, inflammatory, prothrombotic and growth/adhesion markers were measured. The primary endpoint was the change in insulin sensitivity.

Results: A total of 115 patients completed the study. All treatments significantly lowered BP from baseline. Compared with amlodipine, manidipine had significantly superior effects (p<0.05) on insulin resistance (−26.5% vs −3.0%), albumin/creatinine ratio (−28.2% vs −3.6%), low-density lipoprotein (LDL) cholesterol (−6.8% vs +1.7%), and several other metabolic, inflammatory and prothrombotic markers. Manidipine was associated with a slightly greater increase in insulin sensitivity than manidipine/lisinopril, but manidipine/lisinopril was significantly more effective than manidipine and telmisartan for improving a number of metabolic, inflammatory, prothrombotic and growth/adhesion markers. Amlodipine was associated with a significantly greater incidence of adverse effects compared with telmisartan, manidipine and manidipine/lisinopril (26.7% vs 3.3%, 3.3% and 13.3%, respectively).

Conclusion: In patients with hypertension and metabolic syndrome, manidipine, both alone and in combination with the ACE inhibitor lisinopril, is significantly superior to amlodipine for improving insulin sensitivity as well as several metabolic, inflammatory and prothrombotic markers. Furthermore, the combination of manidipine and lisinopril appears to have greater efficacy than manidipine alone and telmisartan with respect to the improvement of metabolic, inflammatory and prothrombotic markers.

Available only for authorised users

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903–13PubMedCrossRef

Leoncini G, Ratto E, Viazzi F, et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005 May; 257(5): 454–60PubMedCrossRef

Pannier B, Thomas F, Bean K, et al. The metabolic syndrome: similar deleterious impact on all-cause mortality in hypertensive and normotensive subjects. J Hypertens 2008 Jun; 26(6): 1223–8PubMedCrossRef

Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004 May 19; 43(10): 1817–22PubMedCrossRef

Vlek AL, van der Graaf Y, Spiering W, et al. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients. J Hum Hypertens 2008 May; 22(5): 358–65PubMedCrossRef

Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep 2009 Apr; 11(2): 150–5PubMedCrossRef

Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010 Sep 28; 56(14): 1113–32PubMedCrossRef

Liu SJ, Guo ZR, Hu XS, et al. Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up. Diabetes Res Clin Pract 2008 Jul; 81(1): 117–23PubMedCrossRef

Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs 2009; 9(3): 163–76PubMed

10.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 Jan 20; 369(9557): 201–7PubMedCrossRef

11.

Buset Rios N, Rodriguez Esparragon F, Rodriguez Perez J. Cardio-metabolic properties of manidipine: beyond lowering arterial pressure? Nefrologia 2009; 29(3): 203–7PubMed

12.

Iimura O, Shimamoto K, Masuda A, et al. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J Diabetes Complications 1995 Oct–Dec; 9(4):215–9PubMedCrossRef

13.

Suzuki S, Ohtomo M, Satoh Y, et al. Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Diabetes Res Clin Pract 1996 Jun; 33(1): 43–51PubMedCrossRef

14.

Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 2004 Jul; 43(7): 561–5PubMedCrossRef

15.

Martinez Martin FJ, Saiz-Satjes M, Rodriguez-Rosas H, et al. Manidipine reduces insulin requirements in hypertensive type 2 diabetic patients [abstract]. J Hypertens 2009; 27Suppl. 4: S132

16.

Luque Otero M, Martell Claros N, on behalf of the Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005 Feb; 27(2): 166–73CrossRef

17.

Martinez Martin FJ. Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. Expert Rev Cardiovasc Ther 2009 Jul; 7(7): 863–9CrossRef

18.

Fogari R, Derosa G, Mugellini A, et al. Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercho-lesterolemic patients [abstract]. ESC Annual Congress; 2008 Aug 30–Sep 3; Munich

19.

Nakami T. PPAR-gamma activation by manidipine mediates enhanced adiponectin production and insulin sensitivity [abstract]. J Hypertens 2006; 24Suppl. 6: 161

20.

Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens 2010 Oct; 28(10): 1983–94PubMed

21.

Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007 Feb 16; 100(3): 342–53PubMedCrossRef

22.

Furukawa T, Nukada T, Miura R, et al. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005 Mar; 45(3): 241–6PubMedCrossRef

23.

Masumiya H, Shijuku T, Tanaka H, et al. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol 1998 May 22; 349(2–3): 351–7PubMedCrossRef

24.

Ott C, Schneider MP, Striepe K, et al. Effects of manidipine versus amlodipine on intraglomerular haemodynamics in patients with hypertension [abstract]. J Hypertens. In press

25.

Fogari R, Mugellini A, Zoppi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albu-minuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 2005 Aug; 61(7): 483–90PubMedCrossRef

26.

Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther 2008 Nov; 6(10): 1347–55PubMedCrossRef

27.

Bellinghieri G, Mazzaglia G, Savica V, et al. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren Fail 2003 Sep; 25(5): 681–9PubMedCrossRef

28.

Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009 Apr; 53(4): 646–53PubMedCrossRef

29.

Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003 Jun 28; 326(7404): 1427–31PubMedCrossRef

30.

Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009 Mar; 122(3): 290–300PubMedCrossRef

31.

Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18(6): 308–47PubMedCrossRef

32.

Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359(23): 2417–28PubMedCrossRef

33.

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005 Sep 24–30; 366(9491): 1059–62PubMedCrossRef

34.

Martin Moreno V, Gomez Gandoy B, Antoranz Gonzalez M, et al. Validation of the OMRON BF 300 monitor for measuring body fat by bioelectric impedance. Aten Primaria 2001 Jul–Aug; 28(3): 174–81

35.

Altunkan S, Iliman N, Altunkan E. Validation of the Omron M6 (HEM-7001-E) upper arm blood pressure measuring device according to the International Protocol in elderly patients. Blood Press Monit 2008 Apr; 13(2): 117–22PubMedCrossRef

36.

Holvoet P. Oxidative modification of low-density lipoproteins in atherothrombosis. Acta Cardiol 1998; 53(5): 253–60PubMed

37.

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 Jun; 27(6): 1487–95PubMedCrossRef

38.

Redon J, Cifkova R, Laurent S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008 Oct; 26(10): 1891–900PubMedCrossRef

39.

Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol 2004 Jul; 27(7 Suppl. 4): IV11–6PubMed

40.

Heidemann C, Sun Q, van Dam RM, et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008 Sep 2; 149(5): 307–16PubMed

41.

Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006 Jan–Feb; 22(1): 4–10PubMedCrossRef

42.

Richy FF, Laurent S. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. Blood Press 2010 Oct 14; doi:10.3109/08037051.2010.518670, PMID: 20945994. Epub

43.

Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009 Jul; 11(7): 376–82CrossRef

44.

Smith DH, Neutel JM, Lacourciere Y, et al. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003 Jul; 21(7): 1291–8PubMedCrossRef

Title: Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome
The MARCADOR Study
Authors: Dr Francisco J. Martinez-Martin
Alicia Macias-Batista
Cristina Comi-Diaz
Herminia Rodriguez-Rosas
Paula Soriano-Perera
Pablo Pedrianes-Martin
Publication date: 01-03-2011
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 3/2011
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/11587590-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome

The MARCADOR Study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers

Importance of C-Reactive Protein Level in Predicting Non-Response to Additional Intravenous Immunoglobulin Treatment in Children with Kawasaki Disease

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

Effects of Structured Follow-Up and of More Effective Acid Inhibitory Treatment in the Management of GORD Patients in a Swedish Primary-Care Setting